People · Operator

Jack L. Stahl

Named in public records as an officer, director or promoter · active 2019–2019 · Pharmaceuticals

1
Companies
1
Filings
$650.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Catalent, Inc.PharmaceuticalsGrowth/Late$650.0M$23.6B2019
Operator network

Jack L. Stahl at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Gregory T. Lucier · 4 companies · 1 sharedGregory T. LucierJ. Martin Carroll · 2 companies · 1 sharedJ. Martin CarrollRolf A. Classon · 2 companies · 1 sharedRolf A. ClassonRosemary A. Crane · 2 companies · 1 sharedRosemary A. CraneAlessandro E. Maselli · 1 companies · 1 sharedAlessandro E. Mas…Christa J. Kreuzburg · 1 companies · 1 sharedChrista J. Kreuzb…Donald E. Morel Jr. · 1 companies · 1 sharedDonald E. Morel J…John J. Greisch · 1 companies · 1 sharedJohn J. GreischJohn R. Chiminski · 1 companies · 1 sharedJohn R. ChiminskiMadhavan L. Balachandran · 1 companies · 1 sharedMadhavan L. Balac…Peter E. Zippelius · 1 companies · 1 sharedPeter E. ZippeliusSteven L. Fasman · 1 companies · 1 sharedSteven L. FasmanWetteny E. Joseph · 1 companies · 1 sharedWetteny E. JosephCatalent, Inc. · $650.0M raisedCatalent, Inc.Jack L. StahlJS
Jack L. Stahl Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Jack L. Stahl on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Gregory T. Lucier14
J. Martin Carroll12
Rolf A. Classon12
Rosemary A. Crane12
Christa J. Kreuzburg11
Donald E. Morel Jr.11
Peter E. Zippelius11
Wetteny E. Joseph11
Alessandro E. Maselli11
Steven L. Fasman11
John R. Chiminski11
Madhavan L. Balachandran11
John J. Greisch11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.